跳至主要内容
临床试验/2024-512893-86-00
2024-512893-86-00已完成1 期

A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PHASE I TRIAL TO INVESTIGATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING TOPICAL DOSES OF GZ21T IN HEALTHY VOLUNTEERS

Ankh Life Sciences Limited1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2024年7月12日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
41
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者
是

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Ankh Life Sciences Limited
申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Cameron West

Scientific

Ankh Life Sciences Limited

研究点 (1)

Loading locations...

相似试验

招募中
1 期
A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participantsCognitive dysfunctionAlzheimer’s diseaseDepression
2025-522287-32-00AlzeCure Pharma AB40
进行中(未招募)
1 期
A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)Peanut allergyMedDRA version: 20.1Level: LLTClassification code 10034202Term: Peanut allergySystem Organ Class: 100000004870
EUCTR2016-003679-23-IEDBV TECHNOLOGIES S.A.400
已完成
3 期
A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)Peanut-allergy10001708
NL-OMON49306DBV Technologies S.A.20
进行中(未招募)
1 期
A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)Peanut allergyMedDRA version: 20.1Level: LLTClassification code 10034202Term: Peanut allergySystem Organ Class: 100000004870
EUCTR2016-003679-23-NLDBV TECHNOLOGIES S.A.400
进行中(未招募)
1 期
A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)Peanut allergyMedDRA version: 20.1Level: LLTClassification code 10034202Term: Peanut allergySystem Organ Class: 100000004870
EUCTR2016-003679-23-FRDBV TECHNOLOGIES S.A.400